Humanized Antibodies Against the α-Chain of the IL-2 Receptor and Against the β-Chain Shared by the IL-2 and IL-15 Receptors in a Monkey Uveitis Model of Autoimmune Diseases

Journal of Immunology

Volumn 158, Issue 1, 1997, Pages 452-458

  Guex Crosier, Yan ^a,c   Raber, James ^b   Chan, Chi Chao ^a   Kriete, Martin S ^b   Benichou, Jacques ^a   Pilson, Robert S ^d   Kerwin, Jo A ^d   Waldmann, Thomas A ^a   Hakimi, John ^d   Roberge, Francois G ^a,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL EYE INSTITUTE   (United States)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d HOFFMANN LA ROCHE INC   (United States)

^e CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; IL15RA PROTEIN, HUMAN; INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 2 RECEPTOR; MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT;

ANIMAL; ARTICLE; AUTOIMMUNE DISEASE; CELL CULTURE; DISEASE MODEL; HAPLORHINI; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; UVEITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; HAPLORHINI; HUMANS; LYMPHOCYTE ACTIVATION; PEPTIDE FRAGMENTS; RECEPTORS, INTERLEUKIN-15; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; UVEITIS;

EID: 0030641530     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Jakubowski, A., B. N. Ehrenfels, R. B. Pepinsky, and L. C. Burkly. 1995. Vascular cell adhesion molecule-Ig fusion protein selectively targets activated alpha 4-integrin receptors in vitro: inhibition of autoimmune diabetes in an adoptive transfer model in nonobese diabetic mice. J. Immunol. 155:938.
2. Yang, X. D., N. Karin, R. Tisch, L. Steinman, and H. O. McDevitt. 1993. Inhibition of insulitis and prevention of diabetes in nonobese diabetic mice by blocking L-selectin and very late antigen 4 adhesion receptors. Prof. Natl. Acad. Sci. USA 90:10494.
3. Nikolic, P. D., H. Y. Lan, V. A. Hill, J. L. Vannice, and R. C. Atkins. 1994. Suppression of experimental glomerulonephritis by the interleukin-1 receptor antagonist: inhibition of intercellular adhesion molecule-1 expression. J. Am. Soc. Nephrol. 4:1695.
4. Gautam, A. M., C. I. Pearson, A. A. Sinha, D. E. Smilek, L. Steinman, and H. O. McDevitt. 1992. Inhibition of experimental autoimmune encephalomyelitis by a nonimmunogenic non-self peptide that binds to I-Au. J. Immunol. 148:3049.
5. Roberge, F. G., H. Lorberboum-Galski, P. Le Hoang, M. De Smet, C. C. Chan, D. Fitzgerald, and I. Pastan. 1989. Selective immunosuppression of activated T cells with the chimeric toxin IL-2-PE40: inhibition of experimental autoimmune uveoretinitis. J. Immunol. 143:3498.
6. Hughes, C., J. A. Wolos, E. H. Giannini, and R. Hirsch. 1994. Induction of T helper cell hyporesponsiveness in an experimental model of autoimmunity by using nonmitogenic anti-CD3 monoclonal antibody. J. Immunol. 153:3319.
7. Bamford, R. N., A. J. Grant, J. D. Burton, C. Peters, G. Kurys, C. K. Goldman, J. Brennan, E. Roessler, and T. A. Waldmann. 1994. The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc. Natl. Acad. Sci. USA 91:4940.
8. Giri, J. G., M. Ahdieh, J. Eisenman, K. Shanebeck, K. Grabstein, S. Kumaki, A. Namen, L. S. Park, D. Cosman, and D. Anderson. 1994. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 13:2822.
9. Matthews, D. J., P. A. Clark, J. Herbert, G. Morgan, R. J. Armitage, C. Kinnon, A. Minty, K. H. Grabstein, D. Caput, P. Ferrara, and R. Callard. 1995. Function of the interleukin-2 (IL-2) receptor gamma-chain in biologic responses of X-linked severe combined immunodeficient B cells to IL-2, IL-4, IL-13, and IL-15. Blood 85:38.
10. Minami, Y., T. Kono, T. Miyazaki, and T. Taniguchi. 1993. The IL-2 receptor complex: its structure, function, and target genes. Annu. Rev. Immunol. 11:245.
11. Grabstein, K. H., J. Eisenman, K. Shanebeck, C. Rauch, S. Srinivasan, V. Fung, C. Beers, J. Richardson, M. A. Schoenborn, M. Ahdieh, L. Johnson, M. R. Alderson, J. D. Watson, D. M. Anderson, and J. G. Giri. 1994. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264:965.
12. Carson, W. E., J. G. Giri, M. J. Lindemann, M. L. Linett, M. Ahdieh, R. Paxton, D. Anderson, J. Eisenmann, K. Grabstein, and M. A. Caligiuri. 1994. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 180:1395.
13. Armitage, R. J., B. M. Macduff, J. Eisenman, R. Paxton, and K. H. Grabstein. 1995. IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J. Immunol. 154:483.
14. Giri, J. G., D. M. Anderson, S. Kumaki, L. S. Park, K. H. Grabstein, and D. Cosman. 1995. IL-15, a novel T cell growth factor that shares activities and receptor components with IL-2. J. Leukocyte Biol. 57:763.
15. Giri, J. G., S. Kumaki, M. Ahdieh, D. J. Friend, A. Loomis, K. Shanebeck, R. DuBose, D. Cosman, L. S. Park, and D. M. Anderson. 1995. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J. 14:3654.
16. Lemm, G., and H. Warnatz. 1986. Evidence for enhanced interleukin 2 (IL-2) secretion and IL-2 receptor presentation by synovial fluid lymphocytes in rheumatoid arthritis. Clin. Exp. Immunol. 64:71.
17. Hofman, F. M., R. I. von Hanwehr, C. A. Dinarello, S. B. Mizel, D. Hinton, and J. E. Merrill. 1986. Immunoregulatory molecules and IL-2 receptors identified in multiple sclerosis brain. J. Immunol. 136:3239.
18. Deschenes, J., D. H. Char, W. Freeman, R. Nozik, and M. Garovoy. 1986. Uveitis: lymphocyte subpopulation studies. Trans. Ophthalmol. Soc. UK 105:246.
19. Scheinberg, M. A., M. Ikejiri, M. H. Silva, and I. M. Mota. 1992. Interleukin 2 receptor membrane bound and in soluble form in the aqueous humor and peripheral blood of patients with acute untreated uveitis. J. Rheumatol. 19:1362.
20. Parenteau, G. L., F. M. Dirbas, K. Garmestani, M. W. Brechbiel, M. A. Bukowski, C. K. Goldman, R. Clark, O. A. Gansow, and T. A. Waldmann. 1992. Prolongation of graft survival in primate allograft transplantation by yttrium-90-labeled anti-Tac in conjunction with granulocyte colony-stimulating factor. Transplantation 54:963.
21. Kirkman, R. L., M. E. Shapiro, C. B. Carpenter, D. B. McKay, E. L. Milford, E. L. Ramos, N. L. Tilney, T. A. Waldmann, C. E. Zimmerman, and T. B. Strom. 1991. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation 51:107.
22. Kirkman, R. L., L. V. Barrett, G. N. Gaulton, V. E. Kelley, A. Ythier, and T. B. Strom. 1985. Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice. J. Exp. Med. 162:358.
23. Kupiec-Weglinski, J. W., T. Diamantstein, N. L. Tilney, and T. B. Strom. 1986. Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats. Proc. Natl. Acad. Sci. USA 83:2624.
24. Banerjee, S., B. Y. Wei, K. Hillman, H. S. Luthra, and C. S. David. 1988. Immunosuppression of collagen-induced arthritis in mice with an anti-IL-2 receptor antibody. J. Immunol. 141:1150.
25. Engelhardt, B., T. Diamantstein, and H. Wekerle. 1989. Immunotherapy of experimental autoimmune encephalomyelitis (EAE): differential effect of anti-IL-2 receptor antibody therapy on actively induced and T-line mediated EAE of the Lewis rat. J. Autoimmun. 2:61.
26. Kelley, V. E., G. N. Gaulton, M. Hattori, H. Ikegami, G. Eisenbarth, and T. B. Strom. 1988. Anti-interleukin 2 receptor antibody suppresses murine diabetic insulitis and lupus nephritis. J. Immunol. 140:59.
27. Chatenoud, L., M. Jonker, F. Villemain, G. Goldstein, and J. F. Bach. 1986. The human immune response to the OKT3 monoclonal antibody is oligoclonal. Science 232:1406.
28. Goldstein, G., A. J. Fuccello, D. J. Norman, C. Shield, R. B. Colvin, and A. B. Cosimi. 1986. OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3. Transplantation 42:507.
29. Winter, G., and W. J. Hams. 1993. Humanized antibodies. Trends Pharmacol. Sci. 14:119.
30. Queen, C., W. P. Schneider, H. E. Selick, P. W. Payne, N. F. Landolfi, J. F. Duncan, N. M. Avdalovic, M. Levitt, R. P. Junghans, and T. A. Waldmann. 1989. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA 86:10029.
31. Hakimi, J., V. C. Ha, P. Lin, E. Campbell, M. K. Gately, M. Tsudo, P. Payne, T. A. Waldmann, A. J. Grant, W.-H. Tsien, and W. O. Schneider. 1993. Humanized Mikβ1, a humanized antibody to the IL-2 receptor β-chain that acts synergistically with humanized anti-Tac. J. Immunol. 151:1075.
32. Junghans, R. P., T. A. Waldmann, N. F. Landolfi, N. M. Avdalovic, W. P. Schneider, and C. Queen. 1990. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res. 50:1495.
33. Brown, P. S. J., G. L. Parenteau, F. M. Dirbas, R. J. Garsia, C. K. Goldman, M. A. Bukowski, R. P. Junghans, C. Queen, J. Hakimi, W. R. Benjamin, R. E. Clark, and T. A. Waldmann. 1991. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. Proc. Natl. Acad. Sci. USA 88:2663.
34. Hakimi, J., R. Chizzonite, D. R. Luke, P. C. Familletti, P. Bailon, J. A. Kondas, R. S. Pilson, P. Lin, D. V. Weber, C. Spence, L. J. Mondini, W.-H. Tsien, J. L. Levin, V. H. Gallati, L. Korn, T. A. Waldmann, C. Queen, and W. R. Benjamin. 1991. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. J. Immunol. 147:1352.
35. Tsudo, M., F. Kitamura, and M. Miyasaka. 1989. Characterization of the interleukin 2 receptor beta chain using three distinct monoclonal antibodies. Proc. Natl. Acad. Sci. USA 86:1982.
36. Salinas-Carmona, M. C., R. B. Nussenblatt, and I. Gery. 1982. Experimental autoimmune uveitis in the athymic nude rat. Eur. J. Immunol. 12:480.
37. Faure, J. P. 1993. Autoimmune diseases of the retina. In The Molecular Pathology of Autoimmune Diseases. C. A. Bona, K. A. Siminovitch, M. Zanetti, and A. N. Theophilopoulos, eds. Harwood Academic, Langhome, p. 651.
38. de Kozak, Y., J. Sakai, B. Thillaye, and J. P. Faure. 1981. S-antigen-induced experimental autoimmune uveoretinitis in rats. Curr. Eye Res. 1:327.
39. Faure, J. P., P. Le Hoang, S. Takano, M. Sterkers, B. Thillaye, and Y. de Kozak. 1981. Experimental uveoretinitis induced in monkeys by retinal S antigen: induction, histopathology (author's translation). J. Fr. Ophtalmol. 4:465.
40. Fujino, Y., Q. Li, H. Chung, N. Hikita, R. B. Nussenblatt, I. Gery, and C.-C. Chan. 1992. Immunopathology of experimental autoimmune uveoretinitis in primates. Autoimmunity 13:303.
41. Hirose, S., T. Kuwabara, R. B. Nussenblatt, B. Wiggert, T. M. Redmond, and I. Gery. 1986. Uveitis induced in primates by interphotoreceptor retinoid-binding protein. Arch. Ophthalmol. 104:1698.
42. Nussenblatt, R. B., A. G. Palestine, C.-C. Chan, and F. Roberge. 1985. Standardization of vitreal inflammatory activity in intermediate uveitis and posterior uveitis. Ophthalmology 92:467.
43. SAS Institute Inc. 1989. SAS/STAT User's Guide, Version 6. SAS Institute, Cary, p. 891.
44. Tinubu, S. A., J. Hakimi, J. A. Kondas, P. Bailon, P. C. Familletti, C. Spence, M. D. Crittenden, G. L. Parenteau, F. M. Dirbas, M. Tsudo, J. D. Bacher, C. Kasten-Sportes, J. L. Martinucci, C. K. Goldman, R. E. Clark, and T. A. Waldmann. 1994. Humanized antibody directed to the IL-2 receptor beta-chain prolongs primate cardiac allograft survival. J. Immunol. 153:4330.
45. Anasetti, C., J. A. Hansen, T. A. Waldmann, F. R. Appelbaum, J. Davis, H. J. Deeg, K. Doney, P. J. Martin, R. Nash, R. Storb, K. M. Sullivan, R. P. Witherspoon, M.-H. Binger, R. Chizzonite, J. Hakimi, D. Mould, H. Satho, and S. E. Light. 1994. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 84:1320.
46. Wang, H. M., and K. A. Smith. 1987. The interleukin 2 receptor: functional consequences of its bimolecular structure. J. Exp. Med. 166:1055.
47. Takeshita, T., H. Asao, K. Ohtani, N. Ishii, S. Kumaki, N. Tanaka, H. Munakata, M. Nakamura, and K. Sugamura. 1992. Cloning of the gamma chain of the human IL-2 receptor. Science 257:379.
48. Audrain, M., F. Boeffard, J. P. Soulillou, and Y. Jacques. 1991. Synergistic action of monoclonal antibodies directed at p55 and p75 chains of the human IL-2-receptor. J. Immunol. 146:884.
49. Duke, R. C., and J. J. Cohen. 1986. IL-2 addiction: withdrawal of growth factor activates a suicide program in dependent T cells. Lymphokine Res. 5:289.
50. Heaton, K. M., and E. A. Grimm. 1995. Differential inhibition of lymphokine-activated killing, proliferation, and cytokine secretion by humanized antibodies against the low-and intermediate-affinity interleukin-2 receptors: a novel model for activation of human peripheral blood mononuclear cells by interleukin 2. Hum. Immunol. 42:274.
51. Schneider, W. P., S. M. Glaser, J. A. Kondas, and J. Hakimi. 1993. The anti-idiotypic response by cynomolgus monkeys to humanized anti-Tac is primarily directed to complementarity-determining regions H1, H2, and L3. J. Immunol. 150:3086.
52. Caron, P. C., J. G. Jurcic, A. M. Scon, R. D. Finn, C. R. Divgi, M. C. Graham, I. M. Jureidini, G. Sgouros, D. Tyson, L. J. Old, M. S. Larson, and D. A. Scheinberg. 1994. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood 83:1760.
53. Riechmann, L., M. Clark, H. Waldmann, and G. Winter. 1988, Reshaping human antibodies for therapy. Nature 332:323.
54. Isaacs, J. D., R. A. Watts, B. L. Hazleman, G. Hale, M. T. Keogan, S. P. Cobbold, and H. Waldmann. 1992. Humanised monoclonal antibody therapy for rheuma-toid arthritis. Lancet 340:748.
55. Lockwood, C. M., S. Thiru, J. D. Isaacs, G. Hale, and H. Waldmann. 1993. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 341:1620.
56. Matteson, E. L., D. E. Yocum, E. W. St. Clair, A. A. Achkar, M. S. Thakor, M. R. Jacobs, A. E. Hays, C. K. Heitman, and J. M. Johnston. 1995. Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. Arthritis Rheum. 38:1187.
57. Weinblatt, M. E., P. J. Maddison, K. J. Bulpitt, B. L. Hazleman, M. B. Urowitz, R. D. Sturrock.,J. S. Coblyn, A. L. Maier, W. R. Spreen, V. K. Manna, and J. M. Johnston. 1995. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis: an intravenous dose-escalation study. Arthritis Rheum. 38: 1589.